| Bioactivity | PZ-2891 is an orally bioavailable, brain penetrant pantothenate kinase (PANK) modulator. PZ-2891 act as an orthosteric inhibitor at high concentrations and an allosteric activator at lower sub-saturating concentrations. PZ-2891 inhibits human pantothenate kinases PANK1β, PANK2, and PANK3 with IC50s of 40.2 nM, 0.7 nM and 1.3 nM, respectively[1]. | ||||||||||||
| Target | IC50: 40.2±4.4 nM (human PANK1β), 0.7±0.08 nM (human PANK2), 1.3±0.2 nM (human PANK3) | ||||||||||||
| Invitro | PZ-2891 inhibits mouse pantothenate kinases PANK1β, PANK2, and PANK3 with IC50s of 48.7±5.1 nM, 1.0±0.1 nM, and 1.9±0.2 nM, respectively[1]. | ||||||||||||
| Name | PZ-2891 | ||||||||||||
| CAS | 2170608-82-7 | ||||||||||||
| Formula | C20H23N5O | ||||||||||||
| Molar Mass | 349.43 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sharma LK, et al. A therapeutic approach to pantothenate kinase associated neurodegeneration. Nat Commun. 2018 Oct 23;9(1):4399. |